Author + information
- Received May 21, 2019
- Revision received August 7, 2019
- Accepted August 14, 2019
- Published online October 28, 2019.
- aDepartment of Medicine, Duke University School of Medicine, Durham, North Carolina
- bDuke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
- ↵∗Address for correspondence:
Dr. Adam D. DeVore, Duke Clinical Research Institute, 200 Morris Street, Durham, North Carolina 27701.
• Wearable health devices are one component of digital and mobile health that have the potential to improve heart failure care and outcomes.
• Current data for heart failure wearables are limited to observational studies and small, randomized controlled trials.
• Wearables are being incorporated into heart failure clinical trials as part of interventions and outcome assessments.
• The key value proposition of wearables is to extend data collection on patients outside of conventional clinical encounters.
The adoption of mobile health (mHealth) devices is creating a unique opportunity to improve heart failure (HF) care. The rise of mHealth is driven by multiple factors including consumerism, policy changes in health care, and innovations in technology. Wearable health devices are one aspect of mHealth that may improve the delivery of HF care by allowing for medical data collection outside of a clinician’s office or hospital. Wearable devices are externally applied and capture functional or physiological data in order to monitor and improve patients’ health. Most wearable sensors capture data continuously and may be incorporated into accessories (e.g., a watch or clothing) or may be applied as a cutaneous patch. Wearable devices are often paired with another device, such as a smartphone, to collect, interpret, or transmit data. This study assessed the potential applications of wearable devices in HF care, summarizes available data for wearables, and discusses the future of wearables for improving the health of patients with HF.
Supported by the Duke Clinical Research Institute, Durham, North Carolina. Dr. DeVore has received research support from AstraZeneca, Amgen, American Heart Association, Bayer, Luitpold Pharmaceuticals, Medtronic, National Heart, Lung, and Blood Institute, Patient-Centered Outcomes Research Institute, and Novartis; and is a consultant for AstraZeneca, LivaNova, Mardil Medical, Novartis, and Procyrion. Dr. Hernandez has received research support from Regent, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, and Verily; and is a consultant for AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Merck, and Novartis. Dr. Wosik has reported that he has no relationships relevant to the contents of this paper to disclose.
- Received May 21, 2019.
- Revision received August 7, 2019.
- Accepted August 14, 2019.
- 2019 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.